The question in the title: What the GIP component of tirzepatide is thought to contribute, and how confident we can be I will give what I have already checked below so nobody repeats it.
I would like to know what people here actually do about GIP component of tirzepatide, as distinct from what is usually recommended. Those have diverged in every other subject I have looked at closely.
Mine is below, with the reasoning, including the parts I am not confident about.
On purity: the trailing-edge features people report on tirzepatide chromatograms are frequently deamidation products, which elute close to the main peak and are easy to integrate into it. That is a method question rather than a quality question.
I have written this out at length because the short version keeps being misread.
Post #3 is right about the mechanism and I think understates the practical bit.
The five maintenance doses in the tirzepatide programme give a genuine dose-response curve, which is unusual. Most trials in this space compare one or two doses against placebo and cannot say anything about the shape of the relationship.
Written quickly, so the reasoning may be tighter than the wording.
Whatever the answer on GIP component of tirzepatide turns out to be, the method for getting there is the same: state the assumption, do the arithmetic in public, invite the correction.
On GIP component of tirzepatide, I would rather understate and be corrected upward than overstate and be quoted. That is a house style here and it is a good one.
I had written a reply contradicting post #3 and deleted it. Here is what survived.
Half-life difference: tirzepatide is about 5 days versus semaglutide's week-long. Practically, that means steady state is reached slightly faster and the post-dose swing is slightly larger. Most people do not report noticing the difference in practical terms.
One of those cases where knowing the mechanism does not help the decision.
Confirming post #7 from a second method, which matters more than confirming it from a second person.
The number people quote for GIP component of tirzepatide is a central estimate presented without its interval, and the interval is wide enough that the estimate is nearly uninformative on its own.
Post #7 and I disagree about the size of the effect, not about the direction.
On the mechanism question specifically: the honest position is that GIP agonism plausibly contributes and that the trial design cannot separate its contribution from simply achieving greater receptor engagement overall.
Correct me on the arithmetic if it is wrong; I would rather know.
Taking post #7 at face value and following it one step further.
Research-use-only tirzepatide is not approved for human use and is not made to pharmaceutical standards. Anyone discussing it here is describing what they did, not recommending it.
I would call that likely rather than established.
I will take the caveat as seriously as the claim, which is the point of putting it there.
SURPASS-2 compared tirzepatide with semaglutide 1.0 mg, the licensed diabetes dose at that time. It did not compare with semaglutide 2.4 mg, the highest approved dose. That is the central and legitimate criticism of the head-to-head evidence and it is worth remembering when people quote the trial.
I had written a reply contradicting post #10 and deleted it. Here is what survived.
Dual agonism versus dose: how much of tirzepatide's effect is the GIP component and how much is simply achieving higher receptor engagement? The honest answer is that the question is not settled. Some of the effect is surely the GIP component, but the trial design does not decompose it.
Worth checking against a second source before it gets quoted onward.
The arithmetic in post #12 is right; the assumption feeding it is the part to check.
The GIP component: GIP receptor agonism is thought to amplify the GLP-1 effect on satiety and energy expenditure, but how much of tirzepatide's effect is that and how much is simply achieving higher receptor occupancy remains genuinely open. The mechanistic literature is active.
Anyone with a larger sample, please post it.
Mass and charge states: tirzepatide is about 4813.5 Da and on an electrospray instrument you would expect to see charge states mostly in the 2+ to 4+ range, the same as semaglutide. A doubly charged species would appear at about (4813.5 + 2 × 1.008) / 2 ≈ 2408.
This is where my knowledge stops and I would rather mark the edge than blur it.
GIP component of tirzepatide is one of those subjects where the general answer and the answer for a specific case diverge, and the thread will go in circles until someone says which one is being asked for.
Tirzepatide's half-life of roughly five days means steady state is approached in about three weeks rather than four. That is a real difference from semaglutide and it is small enough that the weekly schedule is unaffected.
Useful. I have added it to my own notes with the date on it.
Worth separating two things that post #19 runs together.
Categorical response thresholds — the proportion reaching ten, fifteen or twenty per cent reduction — are more persuasive and less informative than the mean. They depend entirely on where the threshold was drawn.
The general case is well covered; this is the awkward specific one.
GIP component of tirzepatide: I would want to see the raw numbers rather than the summary before agreeing. Summaries lose exactly the information that would settle this.
An observation about GIP component of tirzepatide that I cannot explain and am posting anyway, on the principle that unexplained observations are more useful public than private.
Post #23 answers the question as asked. The question underneath it is different.
Heart rate rises modestly across this class, tirzepatide included. It is consistent, small, and worth knowing about rather than worth alarm — and it is one of the reasons the trials monitored it explicitly.
I would rather post the uncertainty than round it away.
Picking up post #23: that is the part I would want checked first.
Categorical response thresholds — the proportion reaching ten, fifteen or twenty per cent reduction — are more persuasive and less informative than the mean. They depend entirely on where the threshold was drawn.
None of the above is medical advice and I am not qualified to give any.
Titration schedules for tirzepatide have more dose steps than semaglutide partly because the compound is more potent and partly because the clinical programme used a finer gradation. That does not mean you cannot escalate on a coarser schedule if that suits you — the published schedule is not a lower bound.
That is clearer than the version I had in my head. Thank you.